Has Themistocles Dassopoulos, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,140,790 in general payments to Themistocles Dassopoulos, MD across 823 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Themistocles Dassopoulos, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Themistocles Dassopoulos, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Themistocles Dassopoulos, MD

Gastroenterology · Dallas, TXNPI 1326083148

Payments from drug & device makers

$1,140,790in general payments, 2019–2025

Across 823 payments — averaging $1386.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$610K
Janssen Research & Development, LLC$207K
E.r. Squibb & Sons, L.L.C.$84K
Bristol Myers Squibb$59K
Eli Lilly$45K
Boehringer Ingelheim$36K
plus $100K from 33 others

What the payments were for

Consulting fees$10,21046%
Travel & lodging$1,9259%
Food & beverage$9,93445%
Education$980%
Gifts$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	362	$609,869
Janssen Research & Development, LLC	73	$206,986
E.r. Squibb & Sons, L.L.C.	7	$84,134
Bristol Myers Squibb	41	$58,828
Eli Lilly	7	$45,237
Boehringer Ingelheim	10	$35,931
Genentech, Inc.	4	$30,848
Pfizer	30	$26,483
Teva Pharmaceuticals USA, Inc.	7	$22,700
Merck	37	$8,723
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	22	$4,476
Takeda Pharmaceuticals U.S.A., Inc.	87	$2,737
Boehringer Ingelheim RCV GmbH & Co KG	3	$1,121
Johnson & Johnson(2 entities)	25	$606
Organon	41	$508
Janssen Scientific Affairs, LLC	6	$287
Aimmune Therapeutics, Inc.	11	$207
Lilly USA, LLC	7	$163
Celltrion USA Inc.	1	$120
Braintree Laboratories, Inc.	7	$113
Medtronic	4	$101
Boston Scientific	2	$82
Amgen	3	$78
Ferring Pharmaceuticals Inc.	4	$68
Mallinckrodt Enterprises LLC	3	$48
Cumberland Pharmaceuticals, Inc.	2	$40
Stryker	1	$36
Shire North American Group Inc	2	$31
Integra Lifesciences Corporation	2	$31
Nestle Healthcare Nutrition Inc.	2	$28
Mallinckrodt Hospital Products Inc.	2	$27
Avanos Medical	1	$22
Intercept Pharmaceuticals, Inc.	1	$21
UCB, Inc.	1	$20
TELA Bio, Inc.	1	$19
AstraZeneca	1	$18
KCI USA, Inc.	1	$17
Endo Pharmaceuticals Inc.	1	$13
Pacira Pharmaceuticals Incorporated	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,140,790 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas →

Medicare billing

Part B allowed, 2024

$350,466

Medicare patients

125

Services billed

13,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Dallas

John FordtranDallas$9.9M
Parvez MantryDallas$6.4M
Michael BrownDallas$5.5M
Jacqueline O LearyDallas$1.4M
Moheb BoktorDallas$1M
Lisa VanwagnerDallas$486K
Rodney InfanteDallas$442K
Eric LawitzSan Antonio$59.5M
George DuvallTyler$17.5M
Timothy RitterSouthlake$7.7M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →